Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX) — AI analysis & news
Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX) stock: 5 recent news items, slightly negative aggregate sentiment, AI analysis and market…
Current sentiment read
Across the last 5 indexed RXRX stories, aggregate finance-aware sentiment is slightly negative (-0.14 on a -1 to +1 scale).
Latest RXRX news
- Recursion Pharmaceuticals Shares Rise After Hours - Goldman Sachs Group (NYSE:GS), Morgan Stanley (NYSE:M - Benzinga · Benzinga
- Recursion Pharmaceuticals director Blake Borgeson sells $242,000 in stock By Investing.com - Investing.com India · Investing.com India
- Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com UK · Investing.com UK
- 25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg. - Stock Titan · Stock Titan
- Is Recursion Pharmaceuticals (RXRX) Stock Fully Priced After Its 87% Fall? - simplywall.st · simplywall.st
FAQ
What is the current sentiment for RXRX stock?
Aggregate finance-aware sentiment across the last 5 indexed RXRX news stories is slightly negative (-0.14 on a -1 to +1 scale).